{"disease":{"id":"hepatitis-c-virus-infection","name":"hepatitis c virus infection"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT05071261","title":"Screening, Treatment, and Eradication of Hep C","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":112136,"lead_sponsor_name":"Liver Institute PLLC","has_results":false},{"nct_id":"NCT06596213","title":"Hepatitis Inequalities Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06155006","title":"Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia","phase":"","overall_status":"RECRUITING","enrollment_count":25669,"lead_sponsor_name":"Asociación Colombiana de Hepatología","has_results":false},{"nct_id":"NCT05906459","title":"Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform\" in China(STAT)","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT03870061","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5187,"lead_sponsor_name":"GiveWell","has_results":false},{"nct_id":"NCT04005248","title":"Prevalence of HCV in HIV-negative MSM","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT06431945","title":"Early Detection of HCV in Injection Drug Users","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Institute of Health Information and Statistics of the Czech Republic","has_results":false},{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT02292706","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","phase":"","overall_status":"TERMINATED","enrollment_count":1609,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04139941","title":"Evaluation Study of HCV RDTs in Fresh Samples","phase":"","overall_status":"COMPLETED","enrollment_count":1540,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT05361603","title":"Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT06718530","title":"Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT04387526","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":946,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04037046","title":"Integrating Hepatitis C Screening With Dried Blood Spot Testing Into Colorectal Cancer Screening","phase":"NA","overall_status":"COMPLETED","enrollment_count":609,"lead_sponsor_name":"University of La Laguna","has_results":false},{"nct_id":"NCT05975216","title":"Relinking Diagnosed But Untreated HCV Patients Back Into Care.","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT07098481","title":"Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":576,"lead_sponsor_name":"ANRS, Emerging Infectious Diseases","has_results":false},{"nct_id":"NCT02537379","title":"Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection","phase":"","overall_status":"COMPLETED","enrollment_count":552,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT05363865","title":"Digital Community to Improve Health in Rural Areas","phase":"NA","overall_status":"COMPLETED","enrollment_count":511,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT02510300","title":"A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials","phase":"","overall_status":"TERMINATED","enrollment_count":461,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT02671500","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":375,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02639247","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":333,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT01939197","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04317729","title":"DBS Evaluation of Fujirebio INNOTEST® HCV Ab IV","phase":"NA","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT04768517","title":"HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT07095192","title":"Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"McGill University","has_results":false},{"nct_id":"NCT02487030","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":255,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02738333","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":239,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03369327","title":"Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Tehran University of Medical Sciences","has_results":false},{"nct_id":"NCT03250910","title":"Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT02249182","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04382937","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT02639338","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03022981","title":"Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04001608","title":"Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":206,"lead_sponsor_name":"Ginkgopharma CO., LTD","has_results":false},{"nct_id":"NCT02378935","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06463912","title":"Screening for Hepatitis c in People Who Inject Drugs in Armenia-Colombia","phase":"","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"Asociación Colombiana de Hepatología","has_results":false},{"nct_id":"NCT02781558","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04677153","title":"Rapid HCV Treatment Access for Persons Who Use Drugs","phase":"NA","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT06859619","title":"Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":183,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04035980","title":"Telemedicine for Linkage to Care People Who Injected Drugs With Hepatitis C","phase":"NA","overall_status":"UNKNOWN","enrollment_count":166,"lead_sponsor_name":"University of La Laguna","has_results":false},{"nct_id":"NCT02472886","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02738138","title":"A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02642432","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT00894257","title":"Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population","phase":"","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT02103439","title":"An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Biocad","has_results":true},{"nct_id":"NCT03453346","title":"Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C","phase":"NA","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Kawin Technology Share-holding Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}